Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLONYSE:DNANASDAQ:KYTXNASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.44+4.3%$1.81$1.30▼$4.25$312.86M0.993.17 million shs3.59 million shsDNAGinkgo Bioworks$5.54-2.8%$9.71$5.00▼$47.60$323.25M1.341.46 million shs1.86 million shsKYTXKyverna Therapeutics$1.98+0.5%$2.70$1.86▼$24.91$85.57M2.57430,481 shs334,476 shsTECXTectonic Therapeutic$15.62-6.3%$28.25$15.00▼$61.07$291.52M2.87168,860 shs172,067 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+4.35%-7.10%-25.39%-33.33%-64.79%DNAGinkgo Bioworks-2.93%-10.04%-32.91%-52.01%-88.06%KYTXKyverna Therapeutics+0.51%-1.00%-25.56%-51.71%-90.97%TECXTectonic Therapeutic-6.30%-16.25%-34.81%-67.81%+1,561,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics2.8467 of 5 stars3.52.00.00.02.84.20.6DNAGinkgo Bioworks0.6146 of 5 stars0.81.00.00.02.02.51.3KYTXKyverna Therapeutics1.4108 of 5 stars3.53.00.00.01.70.00.0TECXTectonic Therapeutic3.1174 of 5 stars3.64.00.00.02.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$9.29545.06% UpsideDNAGinkgo Bioworks 1.60Reduce$4.58-17.39% DownsideKYTXKyverna Therapeutics 3.00Buy$18.33825.93% UpsideTECXTectonic Therapeutic 3.17Buy$77.75397.76% UpsideCurrent Analyst Ratings BreakdownLatest KYTX, DNA, TECX, and ALLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/21/2025TECXTectonic TherapeuticWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$112.00 ➝ $101.003/19/2025ALLOAllogene TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.003/14/2025ALLOAllogene TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.003/14/2025ALLOAllogene TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$5.001/31/2025TECXTectonic TherapeuticWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$79.00 ➝ $112.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$22K14,220.98N/AN/A$3.04 per share0.47DNAGinkgo Bioworks$227.04M1.42N/AN/A$21.93 per share0.25KYTXKyverna Therapeutics$7.03M12.17N/AN/AN/A∞TECXTectonic TherapeuticN/AN/AN/AN/A$2.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$327.27M-$1.33N/AN/AN/AN/A-52.13%-41.29%5/12/2025 (Estimated)DNAGinkgo Bioworks-$892.87M-$10.68N/AN/AN/A-298.78%-58.54%-34.24%5/8/2025 (Estimated)KYTXKyverna Therapeutics-$60.37M-$3.47N/AN/AN/AN/A-51.12%-37.91%5/13/2025 (Estimated)TECXTectonic Therapeutic$12.16M-$6.53N/AN/AN/AN/A-35.53%-31.97%5/8/2025 (Estimated)Latest KYTX, DNA, TECX, and ALLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/A3/20/2025Q4 2024TECXTectonic Therapeutic-$1.39-$0.84+$0.55-$0.84N/AN/A3/13/2025Q4 2024ALLOAllogene Therapeutics-$0.34-$0.28+$0.06-$0.28$0.01 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.359.35DNAGinkgo BioworksN/A5.795.79KYTXKyverna TherapeuticsN/A10.5010.50TECXTectonic TherapeuticN/A9.399.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%DNAGinkgo Bioworks78.63%KYTXKyverna Therapeutics18.08%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics24.30%DNAGinkgo Bioworks9.72%KYTXKyverna TherapeuticsN/ATECXTectonic Therapeutic9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310217.27 million158.72 millionOptionableDNAGinkgo Bioworks64058.03 million51.89 millionOptionableKYTXKyverna Therapeutics9643.22 millionN/AOptionableTECXTectonic Therapeutic12018.66 million13.40 millionN/AKYTX, DNA, TECX, and ALLO HeadlinesRecent News About These CompaniesTectonic Therapeutic Reports Strong 2024 Financial ResultsApril 4 at 12:06 AM | tipranks.comAnalysts Set Tectonic Therapeutic (NASDAQ:TECX) Target Price at $77.75March 28, 2025 | americanbankingnews.comTectonic Therapeutic files to sell 3.69M shares of common stock for holdersMarch 27, 2025 | markets.businessinsider.comTectonic Therapeutic (NASDAQ:TECX) Given Consensus Recommendation of "Buy" by BrokeragesMarch 25, 2025 | marketbeat.comTectonic Therapeutic: Buy Rating Affirmed on Strong Financials and Promising PipelineMarch 24, 2025 | tipranks.comWells Fargo & Company Has Lowered Expectations for Tectonic Therapeutic (NASDAQ:TECX) Stock PriceMarch 22, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPSMarch 21, 2025 | marketbeat.comTectonic Therapeutic: Undervalued Opportunity with Promising Catalysts and Strong Financial PositionMarch 21, 2025 | tipranks.comTectonic Therapeutic Inc (TECX) Reports Q4 2024 Net Loss of $12. ...March 20, 2025 | gurufocus.comTectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent ...March 20, 2025 | gurufocus.comTectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 20, 2025 | globenewswire.comTectonic Therapeutic (NASDAQ:TECX) Stake Trimmed by Atlas Venture Life Science Advisors LLCMarch 7, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Sees Significant Decrease in Short InterestMarch 6, 2025 | marketbeat.comTectonic Therapeutic (TECX) Expected to Announce Quarterly Earnings on ThursdayMarch 6, 2025 | marketbeat.comIs Tectonic Therapeutic, Inc. (TECX) Among Stocks With At Least $20 Million In Insider Spending Recently?March 4, 2025 | insidermonkey.comTectonic Therapeutic, Inc. (TECX): Among the Most Expensive Stocks Insiders Are Buying RecentlyFebruary 22, 2025 | insidermonkey.comTectonic Therapeutic, Inc. (TECX): Among the Most Expensive Stocks Insiders Are Buying RecentlyFebruary 22, 2025 | msn.comTectonic Therapeutic to Participate in March Investor ConferencesFebruary 20, 2025 | markets.businessinsider.comTECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024February 14, 2025 | investorplace.comDeep Track Capital, LP Acquires Significant Stake in Tectonic Therapeutic IncFebruary 10, 2025 | gurufocus.comTectonic Therapeutic director Timothy Springer buys $39.9 million in stockFebruary 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYTX, DNA, TECX, and ALLO Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.44 +0.06 (+4.35%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.45 +0.01 (+0.69%) As of 04/4/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Ginkgo Bioworks NYSE:DNA$5.54 -0.16 (-2.84%) Closing price 04/4/2025 03:59 PM EasternExtended Trading$5.45 -0.09 (-1.57%) As of 04/4/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Kyverna Therapeutics NASDAQ:KYTX$1.98 +0.01 (+0.51%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.99 +0.01 (+0.45%) As of 04/4/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Tectonic Therapeutic NASDAQ:TECX$15.62 -1.05 (-6.30%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$15.91 +0.29 (+1.86%) As of 04/4/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
